Loading
A phase 1/2 trial of R906289 Monosodium (R289 Na) in myelodysplastic syndromes / neoplasms, run by Rigel Pharmaceuticals, now recruiting.
Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) is a phase 1/2 interventional study registered as NCT05308264 by Rigel Pharmaceuticals, with 86 participants planned, started 2022-09-12 and due to reach its primary completion in 2026-08. Interventions recorded: R906289 Monosodium (R289 Na).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Lower-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Lower-risk myelodysplastic syndromes, Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Shares Myelodysplastic syndromes / neoplasms (MDS) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/